Bowel Function After Minimally Invasive Urogynecologic Surgery

University of Rochester

Status

Completed

Conditions

Functional Disorder of Intestine

Treatments

Drug: Docusate

Drug: Bowel medications

Study type

Interventional

Funder types

Other

Identifiers

NCT01044212

29359

Details and patient eligibility

About

The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.

Full description

See above

Enrollment

72 patients

Sex

Female

Ages

18 to 89 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic surgery at Strong Memorial Hospital.

Procedures may include:

robot-assisted laparoscopic sacrocolpopexy
sacrospinous ligament suspension
uterosacral ligament suspension/paravaginal defect repair
colpocleisis
cystocele repair

Additional procedures may include:

hysterectomy
adnexectomy
culdoplasty
minimally invasive sling procedure (TVT or TOT)
periurethral collagen injections
enterocele repair

Exclusion criteria

Planning to undergo laparotomy.
Undergoing rectocele or perineocele repair as part of surgery.
Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.
Presence of a colostomy.
Chronic kidney disease
Insulin-dependent diabetes mellitus
Known cardiac disease
Gastric ulcers
Difficulty swallowing or esophageal stricture
Persistent nausea and vomiting
Signs and symptoms consistent with bowel obstruction